Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Berg · SciRah

Researcher profile · Semantic Scholar

D. Berg

Share profile

D. Berg — researcher profile on SciRah

h-index: 30
Works: 90
Citations: 6,270

Most-cited papers

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Robert J. Mayer, R. B. Davis, C. Schiffer, D. Berg +6 more
1994New England Journal of Medicine1,425 citations Open access
Semantic Scholar
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis +22 more
2016New England Journal of Medicine988 citations Open access
Semantic Scholar
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
C. Bloomfield, David S. Lawrence, J. Byrd, A. Carroll +8 more
1998Cancer Research751 citations
Semantic Scholar
Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
R. Stone, D. Berg, S. George, R. Dodge +6 more
1995437 citations Open access
Semantic Scholar
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +15 more
2014The Lancet Oncology242 citations
Semantic Scholar
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
R. Stone, D. Berg, S. George, R. Dodge +8 more
2001Blood212 citations
Semantic Scholar
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
P. Richardson, R. Baz, Michael L. Wang, A. Jakubowiak +10 more
2014Blood203 citations Open access
Semantic Scholar
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Shaji K. Kumar, W. Bensinger, T. Zimmerman, C. Reeder +8 more
2014Blood195 citations Open access
Semantic Scholar
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
V. Sanchorawala, G. Palladini, V. Kukreti, J. Zonder +11 more
2017Blood112 citations Open access
Semantic Scholar
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
H. Avet-Loiseau, N. Bahlis, W. Chng, T. Masszi +19 more
2017Blood112 citations
Semantic Scholar
Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
E. Rubin, Janet W. Andersen, D. Berg, C. Schiffer +2 more
1992Journal of Clinical Oncology99 citations
Semantic Scholar
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
R. Stone, D. Berg, S. George, R. Dodge +6 more
1995New England Journal of Medicine81 citations
Semantic Scholar
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
P. Richardson, Shaji K. Kumar, T. Masszi, N. Grząśko +18 more
2021Journal of Clinical Oncology75 citations Open access
Semantic Scholar
Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis +21 more
201575 citations
Semantic Scholar
Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Stephen A. Cannistra, J. DiCarlo, P. Groshek, Y. Kanakura +4 more
1991Leukemia74 citations
Semantic Scholar
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B.
R. Mayer, C. Schiffer, B. Peterson, D. Budman +6 more
1987Seminars in Oncology72 citations
Semantic Scholar
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji K. Kumar, P. Moreau, P. Hari, M. Mateos +16 more
2017British Journal of Haematology56 citations Open access
Semantic Scholar
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
M. Mateos, T. Masszi, N. Grząśko, M. Hansson +14 more
2017Haematologica50 citations Open access
Semantic Scholar
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +11 more
2019Leukemia49 citations Open access
Semantic Scholar
A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
A. Dispenzieri, E. Kastritis, A. Wechalekar, S. Schönland +11 more
2021Leukemia48 citations Open access
Semantic Scholar
Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)
A. Dispenzieri, E. Kastritis, A. Wechalekar, S. Schönland +10 more
2019Blood43 citations Open access
Semantic Scholar
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
N. Gupta, P. Diderichsen, M. Hanley, D. Berg +3 more
2017Clinical Pharmacokinetics43 citations Open access
Semantic Scholar
Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma
X. Leleu, T. Masszi, N. Bahlis, L. Viterbo +15 more
2018American journal of hematology/oncology42 citations Open access
Semantic Scholar
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C. Smith, T. Kalebic, J. Infante, L. Siu +13 more
2015Investigational new drugs42 citations Open access
Semantic Scholar
A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +11 more
201142 citations
Semantic Scholar
The patient’s perspective on the symptom and everyday life impact of AL amyloidosis
H. Lin, D. Seldin, A. Hui, D. Berg +2 more
2015Amyloid: Journal of Protein Folding Disorders39 citations
Semantic Scholar
Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data
C. Hofmeister, C. Rosenbaum, M. Htut, D. Vesole +12 more
201338 citations
Semantic Scholar
Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
P. Richardson, C. Hofmeister, C. Rosenbaum, M. Htut +14 more
2018British Journal of Haematology33 citations Open access
Semantic Scholar
Treating Multiple Myeloma Patients With Oral Therapies
Shaji K. Kumar, R. Vij, S. Noga, D. Berg +3 more
2017Clinical Lymphoma, Myeloma & Leukemia32 citations
Semantic Scholar
Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
P. Richardson, R. Baz, Lu-Hua Wang, A. Jakubowiak +6 more
201132 citations
Semantic Scholar
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +12 more
201430 citations
Semantic Scholar
Disease burden of systemic light-chain amyloidosis: a systematic literature review
H. Lin, Xin Gao, C. Cooke, D. Berg +4 more
2017Current Medical Research and Opinion28 citations
Semantic Scholar
Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.
P. Richardson, J. Berdeja, R. Niesvizky, S. Lonial +8 more
201226 citations
Semantic Scholar
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
David P. Ryan, T. Lynch, Michael L. Grossbard, M. Seiden +7 more
2000Cancer25 citations Open access
Semantic Scholar
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
A. Krishnan, K. Patel, P. Hari, S. Jagannath +7 more
2019Blood23 citations Open access
Semantic Scholar
Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
Shaji K. Kumar, W. Bensinger, C. Reeder, T. Zimmerman +7 more
201123 citations
Semantic Scholar
Managing the side effects of chemotherapy for colorectal cancer.
D. Berg
1998Seminars in Oncology22 citations
Semantic Scholar
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)
G. Merlini, V. Sanchorawala, Z. Jeffrey, V. Kukreti +9 more
201420 citations Open access
Semantic Scholar
MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study
G. Merlini, V. Sanchorawala, J. Zonder, V. Kukreti +11 more
201220 citations
Semantic Scholar
A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.
A. Krishnan, K. Patel, P. Hari, S. Jagannath +6 more
202019 citations
Semantic Scholar
New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
P. Richardson, Shaji K. Kumar, J. Laubach, Claudia E. Paba-Prada +4 more
2017Journal of Blood Medicine19 citations Open access
Semantic Scholar
Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation
Ajeeta B. Dash, Jacob Zhang, Lei Shen, Bin Li +7 more
2020European Journal of Haematology18 citations Open access
Semantic Scholar
Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM).
S. Lonial, R. Baz, Michael L. Wang, M. Talpaz +6 more
201218 citations
Semantic Scholar
Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.
Shaji K. Kumar, W. Bensinger, T. Zimmerman, C. Reeder +8 more
201317 citations
Semantic Scholar
New chemotherapy treatment options and implications for nursing care.
D. Berg
1997Oncology Nursing Forum15 citations
Semantic Scholar
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies
M. Dimopoulos, J. Laubach, Maria Asunción Echeveste Gutierrez, N. Grząśko +11 more
2019European Journal of Haematology14 citations
Semantic Scholar
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
L. Garderet, J. Laubach, A. Stoppa, P. Hari +10 more
2018Leukemia14 citations Open access
Semantic Scholar
Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
Shaji K. Kumar, W. Bensinger, C. Reeder, T. Zimmerman +7 more
201213 citations
Semantic Scholar
Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
N. Gupta, M. Hanley, P. Diderichsen, Huyuan Yang +8 more
2018Clinical pharmacology and therapy10 citations Open access
Semantic Scholar
The Cancer and Leukemia Group B Oncology Nursing Committee (1983-2006): A History of Passion, Commitment, Challenge, and Accomplishment
Ellen M. Lavoie Smith, C. Skosey, J. Armer, D. Berg +2 more
2006Clinical Cancer Research10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Hui×19
Invite
A. Hui — researcher profile on SciRah
N. Gupta×19
Invite
N. Gupta — researcher profile on SciRah
Alessandra Di Bacco×18
Invite
Alessandra Di Bacco — researcher profile on SciRah
P. Richardson×16
Invite
P. Richardson — researcher profile on SciRah

×15

Invite

Shaji K. Kumar — researcher profile on SciRah

Guo-Hui Liu×12

Invite

Guo-Hui Liu — researcher profile on SciRah

R. Niesvizky×11

Invite

R. Niesvizky — researcher profile on SciRah

Invite

P. Moreau — researcher profile on SciRah

Jian-Chang Lin×10

Invite

Jian-Chang Lin — researcher profile on SciRah

Invite

P. Hari — researcher profile on SciRah

Invite

S. Lonial — researcher profile on SciRah

H. Van de Velde×8

Invite

H. Van de Velde — researcher profile on SciRah